Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in ...

– Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments – – ADOA is a ...

Optic atrophy is a degenerative disease of the optic nerve that leads to gradual damage to the retinal ganglion cells—the nerve cells that transmit visual signals from the retina to the brain. The ...

A new technology may allow patients to recover vision for conditions that were previously thought irreversible ...

This article deconstructs the IIH guidelines, contrasting medical management (acetazolamide, topiramate) with the practical ...

A noninvasive MRI technique that measures volumetric changes in paraspinal muscles could transform how doctors assess nerve damage in the cervical spine, which helps guide more precise treatment ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the world nearly blind. A new clinical study provides a possible solution that ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...